Lilly, Dicerna Launch $3.7B+ RNAi Collaboration

Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10 targets in cardio-metabolic disease, neurodegeneration, and pain, through a collaboration that could generate more than $3.7 billion for Dicerna, the companies said today.GalXC is designed to advance the development of next-generation RNAi-based therapies that are intended to work by silencing disease-driving gen